Search

Starting this November: EHA Guidelines Workshops!

EHA has initiated a series of online workshops dedicated to guidelines (produced or endorsed by EHA) for diagnosis and treatment of hematologic diseases.

Read more

Social Media Learning

EHA presents our own microlearning in 4 formats, covering diagnosis, pathology, clinical schemas, and clinical cases within topics in the European Hematology Curriculum.

Read more

EHA-JSH Travel Grant

Financial support to help EHA members under 40 attend the Japanese Society of Hematology's Annual Meeting in October 2024.

Read more

15th Annual Sickle Cell and Thalassemia & 1st EHA European Sickle Cell Conference

October 26-31, 2020 | Virtual Global Conference

Steering Committee: B Andemariam, A Campbell, M Cappellini, S Chakravorty,  R Colombatti, B Inusa, R Kesse-Adu, D Rees, A Taher, M Treadwell

In the last week of October, consultants and specialist psychologists, nurses, scientists and…

Read more

15th Annual Sickle Cell and Thalassemia & 1st EHA European Sickle Cell Conference

October 26-31, 2020 | Virtual Global Conference

Steering Committee: B Andemariam, A Campbell, M Cappellini, S Chakravorty,  R Colombatti, B Inusa, R Kesse-Adu, D Rees, A Taher, M Treadwell

In the last week of October, consultants and specialist psychologists, nurses, scientists and…

Read more

EHA-RHS-ROHS Hematology Tutorial 2021

EHA in collaboration with the National Hematological Society (RHS) and the Russian Onco-Hematology Society (ROHS) are closely monitoring the developments concerning the Coronavirus (COVID-19), as our priorities lie with the health and safety of our participants and partners.

Read more

Support opportunities

View the EHA Ranking for 2025

EHA thrives on the support of the biomedical industry and the medical profession. The variety of opportunities available for industry range from educational activities to the EHA Congress.

Read more

SGN-CD33A Combined with Hypomethylating Therapy Produces High Remission Rates among Older Patients with AML

Acute myeloid leukemia (AML) is an aggressive form of blood cancer in which the majority of cases express CD33 on the surface of the leukemia cells.

Read more

Cookie policy

Introduction
When you visit the EHA website and/or EHA’s resource platform(s) (this includes all websites and pages, with the exemption of www. t2evolve.

Read more